# JUN 2 2 2010

SUBMITTED BY:

Kelly French   
Regulatory Affairs Consultant   
Roche Diagnostics   
9115 Hague Road   
Indianapolis, IN 46250   
Phone: (317) 521-3208   
Fax: (317) 521-2324   
Email: kelly.french@roche.com

NAME OF DEVICE:

Trade Name:

Elecsys® Anti-HAV IgM Elecsys® PreciControl anti-HAV IgM

Common Name:

Anti-HAV IgM Test System PreciControl anti-HAV IgM

Classification Name:

Anti-HAV IgM Test System Quality Control Material (Assayed and Unassayed)

Product Code:

LOL, JJX

Predicate Device:

Abbott Axsym HAVAB-M 2.0 Assay (P790019/S011)

DEVICE DESCRIPTION:

Intended Use: The Roche Elecsys Anti-HAV IgM immunoassay is used for the in vitro qualitative detection of IgM antibodies to hepatitis A virus (anti-HAV IgM) in human serum and plasma (potassium EDTA, lithium or sodium heparin, sodium citrate). The assay is intended for use as an aid in the laboratory diagnosis of an acute or recently acquired hepatitis A virus infection.

Assay results, in conjunction with other laboratory results and clinical information, may be used to provide presumptive evidence of infection with hepatitis A virus in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis A infection.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

Kit Description: The Elecsys Anti-HAV IgM immunoassay utilizes a $\mu$ -capture test concept based on a monoclonal h-IgM directed biotinylated antibody, cell culture derived Hepatitis A Virus and a ruthenylated monoclonal antibody directed to HAV. Capture of formed immune complexes from the reaction mixture is based on biotin binding to streptavidin-coated magnetic microparticles which are collected on a measuring cell electrode. Signal generation is triggered by the application of a voltage to the electrode (electrochemiluminescence technology). The level of signal count detected by the system increases as the concentration of the $\mathrm { I g } \mathrm { M }$ antibody target present in a patient sample increases.

The Elecsys PreciControl Anti-HAV IgM contains control serum based on human serum in the negative and positive concentration range. The controls are used for monitoring the accuracy of the Elecsys Anti-HAV IgM immunoassays.

<table><tr><td rowspan=1 colspan=3>Table 1. Anti-HAV IgM Immunoassay Comparison</td></tr><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Elecsys Anti-HAV IgM Assay</td><td rowspan=1 colspan=1>Predicate DeviceAbbott Axsym HAVAB-M 2.0Assay (P790019/S011</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>μ-Capture test principle</td><td rowspan=1 colspan=1>Direct Binding principle</td></tr><tr><td rowspan=1 colspan=1>Detection Protocol</td><td rowspan=1 colspan=1>Electrochemiluminescenceimmunoassay (ECLIA)</td><td rowspan=1 colspan=1>MEIA</td></tr><tr><td rowspan=1 colspan=1>Traceability/Standardization</td><td rowspan=1 colspan=1>Roche Internal Standard</td><td rowspan=1 colspan=1>Not Given</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Human serum and plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatform</td><td rowspan=1 colspan=1>Elecsys 2010(Request for CLIA categorizationhas been made to add theMODULAR ANALYTICS E170,cobas e 411, and cobas e 601analyzers according to theReplacement Reagent andInstrument Policy).</td><td rowspan=1 colspan=1>AxSYM System</td></tr><tr><td rowspan=1 colspan=1>Interpretation ofResults</td><td rowspan=1 colspan=1>≥1.10 Reactive≥ 0.90 - &lt; 1.10 Grayzone&lt;0.9 Negative</td><td rowspan=1 colspan=1>&gt;1.20 Reactive0.80 -1.20 Grayzone&lt;0.80 Nonreactive</td></tr><tr><td rowspan=1 colspan=1>CalibrationInterval</td><td rowspan=1 colspan=1>Once per reagent lot andAfter 1 month (28 days) whenusing the same reagent lotAfter 7 days (when using thesame reagent kit on the analyzer)As required: e.g. quality controlfindings outside the specifiedlimits</td><td rowspan=1 colspan=1>A single sample of both theNegative and Positive Controlsmust be tested as a means ofevaluating the assay calibration.Once the calibration is accepted andstored, all subsequent samples maybe tested without further calibrationunless one or more of the followingoccur:A reagent pack with a new lotnumber is usedEither of the AxSYM HAVAB-M2.0 Control values is out of itsspecified rangeThe MEIA Optics VerificationUpdate has been performed</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Elecsys PreciControl Anti-HAVIgM</td><td rowspan=1 colspan=1>Abbott AxSYM HAVAB-M 2.0Controls</td></tr></table>

# COMPARATIVE TESTING:

A multi-center study was conducted in the U.S. to characterize the performance of the Elecsys Anti-HAV IgM immunoassay. All subjects were tested with the Elecsys AntiHAV IgM assay on the Elecsys 2010 analyzer and with an FDA-cleared reference method in strict accordance with the manufacturer's package insert instructions.

A total of 1087 samples were obtained from multiple specimen sources, representing subjects for whom routine hepatitis A testing had been ordered, hospitalized patients, subjects at increased risk for hepatitis, subjects with signs and symptoms of hepatitis, subjects characterized with acute hepatitis A, and subjects below the age of 21 years (pediatric/adolescents).

The positive percent agreement and the negative percent agreement results for the overall clinical population are presented in the following table:

<table><tr><td rowspan=1 colspan=5>Summary of percent agreements for the various specimen cohorts:Elecsys Anti-HAV IgM results versus 1st reference anti-HAV IgM assayP</td></tr><tr><td rowspan=1 colspan=1>Cohort</td><td rowspan=1 colspan=1>Positive percentagreement % (x/n)</td><td rowspan=1 colspan=1>95 % confidenceinterval</td><td rowspan=1 colspan=1>Negative percentagreement %(x/n)</td><td rowspan=1 colspan=1>95 % confidenceinterval</td></tr><tr><td rowspan=1 colspan=1>Routine HAVtesting</td><td rowspan=1 colspan=1>50.0 (1/2)</td><td rowspan=1 colspan=1>1.26 - 98.7</td><td rowspan=1 colspan=1>99.0 (207/209)</td><td rowspan=1 colspan=1>96.6 - 99.9</td></tr><tr><td rowspan=1 colspan=1>Hospitalized</td><td rowspan=1 colspan=1>00 (0/0)</td><td rowspan=1 colspan=1>0.00- 100</td><td rowspan=1 colspan=1>100 (216/216)</td><td rowspan=1 colspan=1>98.3 - 100</td></tr><tr><td rowspan=1 colspan=1>High risk forhepatitis</td><td rowspan=1 colspan=1>0.00 (0/0)</td><td rowspan=1 colspan=1>0.00 - 100</td><td rowspan=1 colspan=1>100 (215/215)</td><td rowspan=1 colspan=1>98.3 - 100</td></tr><tr><td rowspan=1 colspan=1>Signs andsymptoms</td><td rowspan=1 colspan=1>0.00 (0/0)</td><td rowspan=1 colspan=1>0.00 - 100</td><td rowspan=1 colspan=1>99.5 (211/212)</td><td rowspan=1 colspan=1>97.4 - 99.99</td></tr><tr><td rowspan=1 colspan=1>Characterizedacute HAV</td><td rowspan=1 colspan=1>98.3 (117/119)</td><td rowspan=1 colspan=1>94.1 - 99.8</td><td rowspan=1 colspan=1>73.3 (11/15)</td><td rowspan=1 colspan=1>44.9 - 92.2</td></tr><tr><td rowspan=1 colspan=1>Pediatric/adolescent</td><td rowspan=1 colspan=1>0.00 (0/0)</td><td rowspan=1 colspan=1>0.00 - 100</td><td rowspan=1 colspan=1>100 (99/99)</td><td rowspan=1 colspan=1>96.3 - 100</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>97.5 (118/121)</td><td rowspan=1 colspan=1>92.9 - 99.5</td><td rowspan=1 colspan=1>99.3 (959/966)</td><td rowspan=1 colspan=1>98.5 - 99.7</td></tr></table>

Additional testing was performed for the discrepant and several concordant specimens with a second FDA cleared anti-HAV IgM assay. The second predicate agreed with the Elecsys outcome in 7 of the 10 discrepant samples and with the first predicate in 2 of the 10 specimens. No consensus was obtained in the remaining specimen. Complete concordance was obtained among the three assays in the fifteen nonreactive and reactive concordant specimens also tested.

# ANALYTICAL SENSITIVITY:

Three commercially available HAV seroconversion panels were tested using Elecsys Anti-HAV IgM immunoassay and the FDA approved comparator assay to determine the sensitivity of the assay. Results were also compared with the data supplied by the vendor. The comparator assay and vendor assay are based on the Abbott HAVAB-M. The results are summarized in the following table:

<table><tr><td rowspan=1 colspan=1>Panel ID</td><td rowspan=1 colspan=2>Elecsys 2010 assay</td><td rowspan=1 colspan=2>Comparator anti-HAV IgM assay </td><td rowspan=1 colspan=2>Comparator anti-HAV IgM assay </td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Post bleedday ofearliestreactiveresult</td><td rowspan=1 colspan=1>Post bleed day oflast positive result</td><td rowspan=1 colspan=1>Post bleed dayof earliestreactive result</td><td rowspan=1 colspan=1>Post bleed day oflast positive result</td><td rowspan=1 colspan=1>Post bleed day ofearliest reactiveresult</td><td rowspan=1 colspan=1>Post bleed day oflast positive result</td></tr><tr><td rowspan=1 colspan=1>HAV-01</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>PHT 902Thepanel was nottested with thereference assaydue to thelimited samplesize tested.</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>not tested</td><td rowspan=1 colspan=1>not tested</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>RP013</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>162</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>85</td></tr></table>

c) The comparator results were shown by Roche using the Abbott AxSym HAVAB-M 2.0 assay. d) The comparator results were provided by Vendor using the Abbott HAVAB-M assay.

# EXPECTED VALUES:

The Elecsys Anti-HAV IgM assay was used to evaluate the prevalence of HAV IgM antibodies in an apparently healthy population (normal, healthy individuals without symptoms). The U.S. (New Mexico) and 302 patients were from the low risk region Eastern states of the U.S. (Indiana). The prospective study population was comprised of 208 $( 3 4 . 6 \% )$ males and 394 $( 6 5 . 4 \% )$ females including 493 $( 8 1 . 9 \% )$ Caucasians, 32 $( 5 . 3 \% )$ African Americans, 6 $( 1 . 0 \% )$ Asians, 69 $( 1 1 . 5 \% )$ American Indians and 2 $( 0 . 3 \% )$ unknown. The data has been summarized according to age groups in decades, gender, geographical area and the number of reactive, non-reactive and equivocal results.

<table><tr><td rowspan=1 colspan=9>Expected results for the Elecsys Anti-HAV IgM assay in subjects from low prevalence areas forHepatitis A</td></tr><tr><td rowspan=3 colspan=1>Agerange</td><td rowspan=3 colspan=1>Gender</td><td rowspan=1 colspan=6>Elecsys Anti-HAV IgM results</td><td rowspan=3 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>Reactive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Non-reactive</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Percent</td><td rowspan=1 colspan=1>NN</td><td rowspan=1 colspan=1>Percent</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Percent</td></tr><tr><td rowspan=2 colspan=1>11-20</td><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=2 colspan=1>21-30</td><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=2 colspan=1>31-40</td><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=2 colspan=1>41 -50</td><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=2 colspan=1>51-60</td><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>42</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=2 colspan=1>61 -70</td><td rowspan=1 colspan=1>Fmale</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>51</td></tr><tr><td rowspan=1 colspan=1>Male</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>71-80</td><td rowspan=1 colspan=1>Female</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>48</td></tr></table>

The prevalence rate for reactive anti-HAV IgM antibody in specimens collected in a low prevalence region, Eastern states of the U.S. (Indiana), was $0 . 0 0 \%$ .

<table><tr><td colspan="9" rowspan="1">Expected results for the Elecsys Anti-HAV IgM assay in subjects from high prevalence areas forHepatitis A</td></tr><tr><td colspan="1" rowspan="3">Agerange</td><td colspan="1" rowspan="3">Gender</td><td colspan="6" rowspan="1">Elecsys Anti-HAV IgM results</td><td colspan="1" rowspan="3">Total</td></tr><tr><td colspan="2" rowspan="1">Reactive</td><td colspan="2" rowspan="1">Equivocal</td><td colspan="2" rowspan="1">Non-reactive</td></tr><tr><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">Percent</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">Percent</td><td colspan="1" rowspan="1">N</td><td colspan="1" rowspan="1">Percent</td></tr><tr><td colspan="1" rowspan="2">11 -20</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">8</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">5</td></tr><tr><td colspan="1" rowspan="2">21 -30</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">17</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">11</td></tr><tr><td colspan="1" rowspan="2">31-40</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">27</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="2">41-50</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">52</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">52</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0..00</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">18</td></tr><tr><td colspan="1" rowspan="2">51-60</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">54</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">54</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0..00</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="2">61 -70</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">25</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">4.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">96.0</td><td colspan="1" rowspan="1">25</td></tr><tr><td colspan="1" rowspan="2">71-80</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="2">&gt;80</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">00.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="2">un-known</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.000</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">All ages</td><td colspan="1" rowspan="1">Female</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">000</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">197</td><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">197</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Male</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0.97</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">99.0</td><td colspan="1" rowspan="1">103</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0.33     I</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">299</td><td colspan="1" rowspan="1">99.7</td><td colspan="1" rowspan="1">300</td></tr></table>

Prevalence rate for reactive anti-HAV IgM antibody in specimens collected in a high prevalence region, Western states of,the U.S. (New Mexico), was $0 . 3 3 \%$ .

# PRECISION/REPRODUCIBILITY:

Precision and Reproducibility were determined using Elecsys reagents, human sera, and controls. Precision results were collected on three Elecsys 2010 analyzers using a single lot of reagent. PreciControl Anti-HAV IgM 1 and 2 (PC1 and PC2) materials and three human serum pools (high negative HSP1, low positive HSP2 and moderately positive HSP3) were tested in replicates of 2 in 2 runs/day for 20 days according to the CLSI EP15-A2/EP5-A2.

<table><tr><td rowspan=1 colspan=6>Precision on Elecsys 2010 analyzer</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Intermediate precision</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>Cv</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>HSP1</td><td rowspan=1 colspan=1>0.884</td><td rowspan=1 colspan=1>0.018</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>HSP2</td><td rowspan=1 colspan=1>1.14</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>HSP3</td><td rowspan=1 colspan=1>2.23</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.094</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>PC A-HAVIGM1</td><td rowspan=1 colspan=1>0.230</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>PC A-HAVIGM2</td><td rowspan=1 colspan=1>2.04</td><td rowspan=1 colspan=1>0.050</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.098</td><td rowspan=1 colspan=1>4.8</td></tr></table>

Repeatability $=$ within-run precision 8) Intermediate precision $=$ between-run and between-day variation

<table><tr><td rowspan=1 colspan=6>Precision on MODULAR ANALYTICS E170 analyzers</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Repeatabilityh</td><td rowspan=1 colspan=2>Intermediate precision&#x27;</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>Cv</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>HSPI</td><td rowspan=1 colspan=1>0.929</td><td rowspan=1 colspan=1>0.018</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>HSP2</td><td rowspan=1 colspan=1>1.22</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>4.9</td></tr><tr><td rowspan=1 colspan=1>HSP3</td><td rowspan=1 colspan=1>2.36</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.110</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>PC A-HAVIGM1</td><td rowspan=1 colspan=1>0.217</td><td rowspan=1 colspan=1>0.005</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>PC A-HAVIGM2</td><td rowspan=1 colspan=1>2.13</td><td rowspan=1 colspan=1>0.043</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.110</td><td rowspan=1 colspan=1>5.1</td></tr></table>

h) Repeatability $=$ within-run precision ) Intermediate precision $\mathbf { = }$ between-run and between-day variation

Reproducibility was performed on three external sites on three different Elecsys 2010 and cobas e 411 analyzers. Three human serum pools (high negative HSP3, low positive HSP1 and moderately positive HSP2) were tested in replicates of 3 in 2 runs/day for 5 days according to the CLSI EP15-A2/EP5-A2.

<table><tr><td rowspan=1 colspan=12>Reproducibility on Elecsys 2010 analyzer</td></tr><tr><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=2>Repeat-abilityi</td><td rowspan=1 colspan=2>Inter-mediateprecision</td><td rowspan=1 colspan=2>Between-day</td><td rowspan=1 colspan=2>Between-site</td><td rowspan=1 colspan=2>Repro-ducibility (total)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>|Cv</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>iCV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>cv</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>cv</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>COIm</td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>HSP1</td><td rowspan=1 colspan=1>10.917</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.007</td><td rowspan=1 colspan=1>|0.8</td><td rowspan=1 colspan=1>|0.003</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>|0.023</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>4.3</td></tr><tr><td rowspan=1 colspan=1>HSP2</td><td rowspan=1 colspan=1>1.12</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.025</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>4.3</td></tr><tr><td rowspan=1 colspan=1>HSP3</td><td rowspan=1 colspan=1>2.24</td><td rowspan=1 colspan=1>0.086</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.050</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.104</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=1>PC 1</td><td rowspan=1 colspan=1>0.239</td><td rowspan=1 colspan=1>0.006</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.010</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>5:4</td></tr><tr><td rowspan=1 colspan=1>PC 2</td><td rowspan=1 colspan=1>1.65</td><td rowspan=1 colspan=1>0.049</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.021</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.027</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>5.1</td></tr></table>

Repeatability $=$ within-run precision ) Intermediate precision $=$ between-run " SD $=$ standard deviation $ { \mathfrak { m } } ) _ { \complement \mathrm { O I } } =$ cutoff index EPY ${ \mathfrak { n } } ) _ { \mathsf { P C } } =$ PreciControl A-HAVIGM

<table><tr><td rowspan=1 colspan=12>Reproducibility on MODULAR ANALYTICS E170 analyzer</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Repeat-abiliity</td><td rowspan=1 colspan=2>Inter-mediateprecision</td><td rowspan=1 colspan=2>Between-day</td><td rowspan=1 colspan=2>Between-site</td><td rowspan=1 colspan=2>Repro-ducibility (total)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>sD&#x27;</td><td rowspan=1 colspan=1>Cv</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>cv</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>Cv</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>Cv</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>corm</td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>COI  1</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>COI</td><td rowspan=1 colspan=1>%</td></tr><tr><td rowspan=1 colspan=1>HSP1</td><td rowspan=1 colspan=1>0.923</td><td rowspan=1 colspan=1>0.019</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.020</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.000°</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.031</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>HSP2</td><td rowspan=1 colspan=1>1.13</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.000°</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>0.035</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>HSP3</td><td rowspan=1 colspan=1>2.30</td><td rowspan=1 colspan=1>0.046</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.078</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>0.000°</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.000°</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>0.091</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>PC&quot; 1</td><td rowspan=1 colspan=1>0.213</td><td rowspan=1 colspan=1>0.004</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>0.001</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.016</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>0.017</td><td rowspan=1 colspan=1>|8.0</td></tr><tr><td rowspan=1 colspan=1>PC2</td><td rowspan=1 colspan=1>1.67</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.000°</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.018</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.069</td><td rowspan=1 colspan=1>14.2</td></tr></table>

Repeatability $\mathbf { = }$ within-run precision Intermediate precision $=$ between-run "SD $=$ standard deviation m) $\mathrm { C O I } =$ cutoff index ${ \mathfrak { n } } ) _ { \mathsf { P C } } =$ PreciControl A-HAVIGM $^ { \circ ) } \mathsf { S D }$ u

The specificity of the Elecsys Anti-HAV IgM assay was evaluated by testing a total of 211 specimens representing a variety of disease states (ANA, CMV, EBV, HBV, HCV, HIV, HSV, Mumps/Rubeola, Parvo B19, Rubella, Toxoplasmosis, and VZV).

The testing results are summarized in the table below.

<table><tr><td rowspan=1 colspan=1>Cross- reactant;</td><td rowspan=1 colspan=1>No.tested</td><td rowspan=1 colspan=1>Elecsys Anti-HAV IgM/ReferenceNeg/Neg</td><td rowspan=1 colspan=1>Elecsys Anti-HAV IgM/ReferenceEquivocal/ Neg</td><td rowspan=1 colspan=1>Elecsys Anti-HAV IgM/Reference Neg/Equivocal</td><td rowspan=1 colspan=1>Elecsys Anti-HAV IgM/ReferencePos/Pos</td></tr><tr><td rowspan=1 colspan=1>ANA</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>CMV</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>EBV</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Elevated IgG</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Elevated IgM</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>HBV</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>HCV</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>HIV</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>HSV</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Mumps/ Rubeola</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Parvo B19</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>00</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid factor</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Rubella</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Toxoplasmosis</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>VZV</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>211</td><td rowspan=1 colspan=1>209</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr></table>

HAMA effect was tested by comparing the recovery of 10 human serum samples spiked with HAMA versus 10 unspiked aliquots of samples: $\aleph o$ HAMA effect was found.

# POTENTIALLY INTERFERING SUBSTANCES:

The assay is unaffected by icterus (bilirubin $< 8 5 5 ~ \mu \mathrm { m o l / L }$ or $< 5 0 ~ \mathrm { m g / d L }$ , hemolysis ( $\mathrm { H b } <$ $0 . 6 2 3 ~ \mathrm { m m o l / L }$ or $< 1 . 0 \ \mathrm { g / d L }$ ), lipemia (Intralipid $< 2 0 0 0 ~ \mathrm { m g / d L } )$ , and biotin $< 2 0 5 \ \mathrm { n m o l / L }$ or $< 5 0$ EPY $\mathfrak { n g / \mathrm { m L } }$ . There is no high-dose hook effect up to 16 COI.

In vitro tests were performed on 18 commonly used pharmaceuticals (Acetylcystein, Ampicillin, Ascorbic acid, Ca- Dobesilate, Cyclosporine, Cefoxitin, Heparin, Intralipid, Levodopa, Methyldopa, Metronidazole, Phenylbutazone, Tetracycline, Acetylsalicylic Acid, Rifampicin, Acetaminophen, Ibuprofen, Theophylline). No interference with the assay was found.

# SERUM AND PLASMA COMPARISON:

The following tables summarize the results for the comparison between serum and 4 plasma matrices.

<table><tr><td colspan="1" rowspan="1">Plasma matrix</td><td colspan="3" rowspan="1">Number of positive specimens showing recovery to serum withinvarious ranges</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">&lt;10 %</td><td colspan="1" rowspan="1">10 - 15 %</td><td colspan="1" rowspan="1">&gt; 15 %</td></tr><tr><td colspan="1" rowspan="1">Li-heparin</td><td colspan="1" rowspan="1">[9</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Na-heparin</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">K2-EDTA</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Sodium citrate</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Plasma matrix</td><td colspan="3" rowspan="1">Number of borderline specimens showing recovery to serum withinvarious ranges</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">&lt;10 %</td><td colspan="1" rowspan="1">10 - 15 %</td><td colspan="1" rowspan="1">&gt; 15%</td></tr><tr><td colspan="1" rowspan="1">Li-heparin</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Na-heparin</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">K2-EDTA</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Sodium citrate</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Plasma matrix</td><td rowspan=1 colspan=3>Number of negative specimens showing recovery to serum withinvarious ranges</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>&lt;0.1 COI</td><td rowspan=1 colspan=1>0.1 - 0.3 COI</td><td rowspan=1 colspan=1>&gt; 0.3 COI</td></tr><tr><td rowspan=1 colspan=1>Li-heparin</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Na-heparin</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Sodium citrate</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr></table>

Ms. Kelly French, RN, BSN, RAC   
Regulatory Affairs Consultant   
Roche Diagnostics   
Roche Professional Diagnostics   
9115 Hague Road   
Indianapolis, IN 46250-0416

# JUN 2 2 2010

Re: K093955 Trade/Device Name: Elecsys® Anti-HAV IgM Elecsys® PreciControl Anti-HAV IgM Regulation Number: 21 CFR $\ S 8 6 6 . 3 3 1 0$ 21 CFR $\ S 8 6 2 . 1 6 6 0$ EP Regulation Name: Hepatitis A Virus Serological Assays Quality Control Material Regulatory Class: Class II Product Code: LOL. JJX Dated: March 23, 2010 Received: March 24, 2010

Dear Ms. French:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class Ⅱ (Special Controls) or class ⅢI (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours, Me Sf A

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

# Indication for Use

510(k) Number: K093955

Device Name: Elecsys Anti-HAV IgM Assay

Indication For Use:

The Roche Elecsys Anti-HAV IgM immunoassay is used for the in vitro qualitative detection of IgM antibodies to hepatitis A virus (anti-HAV IgM) in human serum and plasma (potassium EDTA, lithium or sodium heparin, sodium citrate). The assay is intended for use as an aid in the laboratory diagnosis of an acute or recently acquired hepatitis A virus infection.

Assay results, in conjunction with other laboratory results and clinical information, may be used to provide presumptive evidence of infection with hepatitis A virus in persons with signs and symptoms of hepatitis and in persons at risk for hepatitis A infection.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

Device Name: Elecsys Anti-HAV IgM PreciControl

Indication For Use:

Elecsys PreciControl Anti-HAV IgM is used for quality control of the Elecsys Anti-HAV IgM immunoassay on the Elecsys and cobas e immunoassay analyzers.

Prescription Use X And/Or Over the Counter Use (21 CFR Part 801 Subpart D) (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Offjce of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/bfbe7830994227039cb57c5ca0c85fdeaba94318f77cda9db4a8ebea6fba8868.jpg)

Division Sign-Off V Office of In Vitro Diagnostic Device Evaluation and Safety